AC Immune SA (ACIU)

NASDAQ: ACIU · IEX Real-Time Price · USD
3.16
-0.13 (-3.95%)
Sep 30, 2022 4:00 PM EDT - Market closed
-3.95%
Market Cap 263.59M
Revenue (ttm) n/a
Net Income (ttm) -79.67M
Shares Out 83.41M
EPS (ttm) -1.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 88,906
Open 3.27
Previous Close 3.29
Day's Range 2.96 - 3.29
52-Week Range 2.06 - 8.14
Beta 0.71
Analysts Buy
Price Target 10.88 (+244.3%)
Earnings Date Nov 7, 2022

About ACIU

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Ph... [Read more...]

Industry Biotechnology
IPO Date Sep 23, 2016
CEO Andrea Pfeifer
Employees 137
Stock Exchange NASDAQ
Ticker Symbol ACIU
Full Company Profile

Financial Performance

Financial numbers in CHF Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for ACIU stock is "Buy." The 12-month stock price forecast is 10.88, which is an increase of 244.30% from the latest price.

Price Target
$10.88
(244.30% upside)
Analyst Consensus: Buy
Stock Forecasts

News

AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage Development in Alzheimer's Disease

LAUSANNE, Switzerland, Sept. 26, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today anno...

5 days ago - GlobeNewsWire

AC Immune KOL Webinar on the Potential Benefits of Vaccines for Alzheimer's and Parkinson's Diseases

LAUSANNE, Switzerland, Aug. 24, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (Nasdaq: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today hoste...

1 month ago - GlobeNewsWire

Detailed Data From the Phase II Crenezumab Alzheimer's Prevention Initiative Study in Autosomal Dominant Alzheimer's ...

LAUSANNE, Switzerland, Aug. 02, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (Nasdaq: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today annou...

1 month ago - GlobeNewsWire

AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

AC Immune Reports Second Quarter 2022 Financial Results and Provides Corporate Update

LAUSANNE, Switzerland, July 28, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today repor...

2 months ago - GlobeNewsWire

AC Immune Announces Upcoming Presentations at the Alzheimer's Association International Conference

LAUSANNE, Switzerland, July 22, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases,...

2 months ago - GlobeNewsWire

AC Immune Holds Annual General Meeting of Shareholders

LAUSANNE, Switzerland, June 24, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today annou...

3 months ago - GlobeNewsWire

AC Immune shares slide 15% premarket after trial of Alzheimer's treatment misses its main goals

Shares of biotech AC Immune SA ACIU, -9.21% slid 15% in premarket trade Thursday, after the company said a a trial of a treatment for Alzheimer's disease failed to slow or prevent cognitive decline in p...

3 months ago - Market Watch

AC Immune Provides Update on Alzheimer's Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzh...

Crenezumab did not statistically significantly slow or prevent cognitive decline in people with a specific genetic mutation which causes early-onset Alzheimer's disease

3 months ago - GlobeNewsWire

AC Immune to Present at the 2022 Jefferies Healthcare Conference

LAUSANNE, Switzerland, May 31, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announ...

4 months ago - GlobeNewsWire

AC Immune Reports First Quarter 2022 Financial Results and Provides Corporate Update

Two clinical readouts delivered in Q1; five more expected by year-end

5 months ago - GlobeNewsWire

AC Immune to Present at the B. Riley Annual Neuro & Ophthalmology Virtual Investor Conference

LAUSANNE, Switzerland, April 27, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today anno...

5 months ago - GlobeNewsWire

AC Immune Reports Changes to Senior Management

Howard Donovan appointed Chief HR Officer, joins executive committee

5 months ago - GlobeNewsWire

AC Immune Reports Full Year 2021 Financial Results and Provides Corporate Update

Seven clinical data readouts expected in 2022 Three vaccines, targeting Tau, Abeta and alpha-synuclein, advancing in 2022 Semorinemab Phase 2 Lauriet trial: additional fluid biomarker data expected in H...

6 months ago - GlobeNewsWire

AC Immune to Host Key Opinion Leader Webinar on Alpha-Synuclein as a Target in Neurodegenerative Diseases

Webinar to take place on Tuesday, March 29th at 10:00 AM ET / 4:00 PM CET Webinar to take place on Tuesday, March 29th at 10:00 AM ET / 4:00 PM CET

6 months ago - GlobeNewsWire

AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disea...

ACI-12589 distinguished multiple system atrophy (MSA) from other a-synucleinopathies and healthy volunteers

6 months ago - GlobeNewsWire

AC Immune to Present at the AD/PD™ 2022 New Clinical and Preclinical Data for Alpha-Synuclein, Abeta and TDP-43 Programs

Five presentations at the International Conference on Alzheimer's & Parkinson's Diseases (AD/PD TM )

7 months ago - GlobeNewsWire

AC Immune-Janssen Partnered Alzheimer's Vaccine Shows Tau-Specific Antibodies In Early-Stage Trial

AC Immune SA (NASDAQ: ACIU) and partner Janssen, a unit of Johnson & Johnson (NYSE: JNJ), have found that an early-stage Alzheimer's vaccine spurs induction of antibodies that attack a type of tau, a pr...

7 months ago - Benzinga

AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzhe...

Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment

7 months ago - GlobeNewsWire

AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Ke...

Results differentiate ACI-24 as potential best-in-class Abeta vaccine in development

7 months ago - GlobeNewsWire

AC Immune to Present at the SVB Leerink 11th Annual Global Healthcare Conference

LAUSANNE, Switzerland, Feb. 02, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today annou...

7 months ago - GlobeNewsWire

AC Immune Announces Interim Phase 1b/2a Data Showing that its ACI-35.030 Anti-pTau Alzheimer's Vaccine Generates a Po...

Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment

10 months ago - GlobeNewsWire

AC Immune Announces Late-Breaker Presentation by Genentech at CTAD on Phase 2 Lauriet Study of Semorinemab in Mild-to...

Analysis of the broader mITT population is consistent with the previously reported success in meeting one of the two co-primary endpoints (ADAS-Cog11) with statistically significant reduction in the rat...

10 months ago - GlobeNewsWire

AC Immune (ACIU) Reports Q3 Loss, Misses Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of 17.24% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

AC Immune Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Announced the first positive cognitive results for a Tau-targeting monoclonal antibody in mild-to-moderate Alzheimer's disease

10 months ago - GlobeNewsWire